Reported 8 months ago
Novo Nordisk, the maker of Wegovy, plans to spend $4.1 billion to construct a facility in the US for filling injection pens for their weight-loss treatment Wegovy and diabetes drug Ozempic. The plant in Clayton, North Carolina, is expected to be completed between 2027 and 2029, creating 1,000 new jobs. The investment aims to meet the growing demand for Wegovy in the US and other markets and expand Novo's manufacturing capacity.
Source: YAHOO